Compare ELMD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | CHRS |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.1M | 209.8M |
| IPO Year | 2010 | 2014 |
| Metric | ELMD | CHRS |
|---|---|---|
| Price | $38.08 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.00 | $5.51 |
| AVG Volume (30 Days) | 48.4K | ★ 845.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.55 | ★ 472.00 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $15.59 | $73.08 |
| Revenue Next Year | $11.51 | $30.94 |
| P/E Ratio | $40.92 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $17.73 | $0.72 |
| 52 Week High | $40.00 | $2.62 |
| Indicator | ELMD | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 45.48 |
| Support Level | $23.47 | $1.37 |
| Resistance Level | $40.00 | $1.75 |
| Average True Range (ATR) | 1.98 | 0.08 |
| MACD | -0.38 | 0.00 |
| Stochastic Oscillator | 64.75 | 41.90 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.